Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

PURPOSE: We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic therapies with clinical benefit. M...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Oncol
Hoofdauteurs: Subbiah, Vivek, Kreitman, Robert J., Wainberg, Zev A., Cho, Jae Yong, Schellens, Jan H.M., Soria, Jean Charles, Wen, Patrick Y., Zielinski, Christoph, Cabanillas, Maria E., Urbanowitz, Gladys, Mookerjee, Bijoyesh, Wang, Dazhe, Rangwala, Fatima, Keam, Bhumsuk
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Clinical Oncology 2018
Onderwerpen:
RAPID COMMUNICATION
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5791845/
https://ncbi.nlm.nih.gov/pubmed/29072975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.6785
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items